Inspire Medical Stock Price, News & Analysis

Inspire Medical Systems (NYSE: INSP) announced updates to the 2022 reimbursement payment rates for procedures performed in Ambulatory Surgical Centers (ASCs). Effective January 1, 2022, the national average reimbursement for CPT code 64582, assigned for Inspire's hypoglossal nerve stimulation treatment, will be $24,828.64, with a device offset percentage of 88.07%. This update follows CMS's correction of a previously miscalculated device offset. CEO Tim Herbert expressed gratitude towards CMS for the prompt updates, providing clarity for ASCs and enabling them to schedule procedures without reimbursement uncertainties.

Inspire Medical Systems reported a remarkable 72% revenue increase to $61.7 million for Q3 2021, driven by growing demand and the activation of 68 new centers, totaling 603 in the U.S. The gross margin improved to 86.0%, up from 85.5% a year prior. The company raised its full year 2021 revenue guidance to $219 million to $221 million, reflecting a potential growth of 90% to 92% compared to 2020. Despite a net loss of $10.3 million, cash reserves remain strong at $220.2 million. Inspire is optimistic about ongoing demand and reimbursement improvements for its therapy.

Inspire Medical Systems, a leader in medical technology for obstructive sleep apnea, will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 10:40 a.m. ET. The presentation will be available via a live webcast, and a replay will be accessible for two weeks on Inspire's Investor website.

Inspire's innovative therapy, the first FDA-approved neurostimulation method for moderate to severe obstructive sleep apnea, underscores their commitment to developing minimally invasive solutions for patients.

Inspire Medical Systems, a medical technology leader in obstructive sleep apnea solutions, will present at the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 8:00 a.m. Eastern Time. The presentation can be accessed via a live webcast and will be available for replay for two weeks on their Investor website. Inspire’s proprietary Inspire therapy is the only FDA-approved neurostimulation technology offering a safe treatment for moderate to severe obstructive sleep apnea.

Inspire Medical Systems (NYSE: INSP) announced it will release its third quarter 2021 financial results on November 2, 2021, after market close. A conference call to discuss these results and recent business developments will follow at 5:00 p.m. ET. Inspire focuses on innovative solutions for obstructive sleep apnea, with its Inspire therapy being the first FDA-approved neurostimulation treatment for moderate to severe cases. For more information, visit www.inspiresleep.com.

Inspire Medical Systems (NYSE: INSP) is dedicated to advancing quality in obstructive sleep apnea treatment during Quality Week, enhancing its commitment to patient outcomes. CEO Tim Herbert emphasizes the company's focus on innovation and the launch of its first historical Patient Experience Report, providing transparency on clinical outcomes. This initiative aims to assist both physicians and patients in making informed treatment choices. Inspire's proprietary therapy remains the only FDA-approved neurostimulation option for moderate to severe sleep apnea, ensuring safe and effective treatment.

Inspire Medical Systems (NYSE: INSP) announced a favorable recommendation from a CMS panel to increase reimbursement for its obstructive sleep apnea procedures in Ambulatory Surgical Centers (ASCs). The CMS panel unanimously supported resetting the device offset rate to 85.71%, reversing a proposed reduction to $17,500 from nearly $25,000. This decision contrasts with a hospital reimbursement increase to over $30,000. The final reimbursement rates are anticipated to be published later in 2021 and effective January 1, 2022.

Inspire Medical Systems, a leader in medical technology, will present at the Wells Fargo 2021 Virtual Healthcare Conference on September 9, 2021, at 2:00 p.m. Eastern Time. The presentation will focus on their innovative and minimally invasive solutions for obstructive sleep apnea. Interested parties can access the live webcast here. A replay will be available for two weeks on Inspire's Investor website. Inspire's therapy is the only FDA-approved neurostimulation treatment for moderate to severe obstructive sleep apnea.

Inspire Medical Systems (NYSE: INSP) reported a strong second quarter of 2021, with revenue reaching $53.0 million, up 335% year-over-year. Gross margin increased to 85.8%, reflecting improved sales volumes. The company activated 63 new U.S. centers and created 13 new sales territories, surpassing prior guidance. Due to positive trends, Inspire raised its full year revenue guidance to $210-$213 million, indicating 82%-85% growth over 2020. Despite a net loss of $13.1 million, cash reserves remained solid at $217.8 million.